Sibylle Loibl, Chief Executive Officer at the German Breast Group Research Company (GBG Forschungs GmbH), shared a post on LinkedIn:
“Publication in the NEJM: Important data for HR+/ HER2+ metastatic breast cancer
The phase 3 PATINA trial (NCT02947685, GBG94, AFT38), now published in The New England Journal of Medicine, presents practice-changing results for patients with hormone receptor–positive, HER2-positive metastatic breast cancer.
Study concept
The trial evaluated whether adding palbociclib to maintenance therapy (anti-HER2 plus endocrine therapy) after initial chemotherapy provides additional benefit.
Key findings
Significant improvement in progression-free survival (PFS)
44.3 months vs. 29.1 months (HR for disease progression or death 0.75; two-sided p = 0.02)
As expected, higher rates of grade 3/4 adverse events, predominantly neutropenia.
Conclusion
The addition of palbociclib significantly prolongs progression-free survival, with a manageable and well-known safety profile.
These results may meaningfully impact first-line maintenance strategies in HR+/HER2+ metastatic breast cancer.
A sincere thank you to all study groups, investigators, and patients who made this important research possible.”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Lisa Carey
Read the Full Article.
Other OncoDaily articles featuring Sibylle Loibl.